Silo Pharma Inc. (SILO)
NASDAQ (CM) NASDAQ (CM) Primary Summary
Why Is Silo Pharma (SILO) Stock Up 60% Today?
Developmental-stage pharmaceutical firm Silo Pharma (NASDAQ: SILO ) — which specializes in both traditional and psychedelic therapeutics to address stress-induced psychiatric disorders — saw its shares rise dramatically on Thursday. Earlier this morning, the company announced a partnership to develop an intranasal drug to address post-traumatic stress disorder (PTSD).
Silo Pharma Finds Partner For Device Development for Intranasal PTSD Drug
Silo Pharma Inc SILO stock is surging on Thursday, with a session volume of 88 million compared to an average volume of 3.2 million, as per data from Benzinga Pro.
Why Is Nano-Cap Silo Pharma Stock Skyrocketing On Tuesday?
Silo Pharma Inc SILO shares are trading higher on Tuesday on a high session volume of over 87 million.
Silo Pharma Inc. (SILO) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Silo Pharma Inc. ever had a stock split?
Silo Pharma Inc. Profile
| Biotechnology Industry | Healthcare Sector | Eric Weisblum CEO | NASDAQ (CM) Exchange | 82711P300 CUSIP |
| US Country | 3 Employees | - Last Dividend | 3 Jun 2026 Last Split | 13 May 2014 IPO Date |
Overview
Silo Pharma, Inc. operates as a developmental stage biopharmaceutical company with a keen focus on integrating traditional therapeutic practices with innovative psychedelic research. Since its incorporation in 2010 and subsequent name change from Uppercut Brands, Inc. to Silo Pharma, Inc. in September 2020, the company has dedicated itself to exploring and developing new solutions for various underserved medical conditions. By strategically merging classical therapeutic methodologies with the emerging field of psychedelic studies, Silo Pharma aims to address complex health issues, such as mental health disorders, depression, and rare neurological conditions, including Alzheimer's and Parkinson's diseases. Based in Englewood Cliffs, New Jersey, the company positions itself at the intersection of traditional medicine and psychedelic science, seeking to revolutionize treatment approaches for patients suffering from several indications that have historically been challenging to manage effectively.
Products and Services
Silo Pharma, Inc. is committed to pioneering the development of therapeutic solutions that incorporate both traditional and psychedelic research approaches. The company's focus areas include:
- Psychedelic Research for Mental Health: Silo Pharma is exploring the therapeutic potential of psychedelic substances like psilocybin in treating mental health issues, such as depression and post-traumatic stress disorder (PTSD). The aim is to unlock new pathways for intervention that can provide relief where conventional treatments might not have been fully effective.
- Rare Neurological Disorders: With a special focus on Alzheimer's, Parkinson's, and other rare neurological disorders, the company is investing in research and development to understand how psychedelic drugs can contribute to managing these complex conditions. Silo Pharma's initiatives are driven by the belief that psychedelics could offer significant benefits in terms of symptom management and quality of life improvement for individuals affected by these diseases.
- Intellectual Property and Technology Acquisition: Beyond its direct research efforts, Silo Pharma also engages in acquiring and/or developing intellectual property or technology rights. These efforts primarily target innovations emerging from universities and research institutions that have the potential to treat rare diseases using psychedelic drugs. This strategic approach allows Silo Pharma to broaden its reach and impact across different domains of the medical and therapeutic landscape.
